Novo Nordisk Announces Semaglutide Price Reduct...

By João L. Carapinha

February 26, 2026

Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per ...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Transformative PBM Reform Legislation Signed into Law
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
Novartis Drug Pricing Agreement
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...